Cardiomyopathy cost-effectiveness of therapy: Difference between revisions
No edit summary |
Lina Yaqoub (talk | contribs) |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually. | |||
==References== | ==References== | ||
| Line 11: | Line 13: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
{{Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu}} | |||
Revision as of 18:16, 16 December 2018
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy cost-effectiveness of therapy |
|
Risk calculators and risk factors for Cardiomyopathy cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
The cost-effectiveness of different management options depends on the associated risk factors and risk for sudden cardiac death. Most patients with cardiomyopathies are treated similar to heart failure patients, although some do not respond well and might need heart transplantation eventually.
References
Template:WH Template:WS Template:Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Citation data: American heart journal, ISSN: 1097-6744, Vol: 154, Issu